Stephen Castaneda

2.2k total citations
14 papers, 685 citations indexed

About

Stephen Castaneda is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Stephen Castaneda has authored 14 papers receiving a total of 685 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 4 papers in Molecular Biology and 4 papers in Cancer Research. Recurrent topics in Stephen Castaneda's work include HER2/EGFR in Cancer Research (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and Cancer Treatment and Pharmacology (4 papers). Stephen Castaneda is often cited by papers focused on HER2/EGFR in Cancer Research (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and Cancer Treatment and Pharmacology (4 papers). Stephen Castaneda collaborates with scholars based in United States, Germany and Belgium. Stephen Castaneda's co-authors include Ivan Inigo, David Kan, Christine Flefleh, Amy Camuso, Kelly McGlinchey, Krista Fager, Robert A. Kramer, Mei-Li Wen, Xiaohong Xu and Gregory D. Plowman and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Stephen Castaneda

14 papers receiving 670 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stephen Castaneda United States	10	356	217	146	143	134	14	685
Ivan Inigo United States	10	363 1.0×	225 1.0×	160 1.1×	110 0.8×	146 1.1×	21	693
Jamie L. DellaGatta United States	6	299 0.8×	273 1.3×	293 2.0×	67 0.5×	81 0.6×	8	658
Richard Smykla United States	11	279 0.8×	202 0.9×	68 0.5×	83 0.6×	224 1.7×	16	637
Paul A. Algate United States	7	146 0.4×	269 1.2×	100 0.7×	112 0.8×	68 0.5×	12	528
Ruth Seggewiss‐Bernhardt Germany	12	409 1.1×	434 2.0×	214 1.5×	232 1.6×	87 0.6×	19	889
Glenn Michelson United States	14	282 0.8×	340 1.6×	112 0.8×	72 0.5×	146 1.1×	51	668
Konrad Aumann Germany	16	220 0.6×	346 1.6×	134 0.9×	70 0.5×	163 1.2×	41	731
Yves Toiron France	13	236 0.7×	423 1.9×	112 0.8×	66 0.5×	251 1.9×	21	823
Sophie Derenne France	8	362 1.0×	418 1.9×	159 1.1×	44 0.3×	338 2.5×	11	780
Marijn Bögels Netherlands	13	484 1.4×	336 1.5×	505 3.5×	69 0.5×	279 2.1×	20	1.1k

Countries citing papers authored by Stephen Castaneda

Since Specialization

Citations

This map shows the geographic impact of Stephen Castaneda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen Castaneda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen Castaneda more than expected).

Fields of papers citing papers by Stephen Castaneda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen Castaneda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen Castaneda. The network helps show where Stephen Castaneda may publish in the future.

Co-authorship network of co-authors of Stephen Castaneda

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen Castaneda. A scholar is included among the top collaborators of Stephen Castaneda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen Castaneda. Stephen Castaneda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Holmgaard, Rikke, David Schaer, Yanxia Li, et al.. (2018). Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade. Journal for ImmunoTherapy of Cancer. 6(1). 47–47. 267 indexed citations

Schaer, David, Yanxia Li, Stephen Castaneda, et al.. (2016). Abstract A091: Targeting the TGFb pathway with galunisertib, a TGFbRI SMI, promotes antitumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition. Cancer Immunology Research. 4(1_Supplement). A091–A091. 1 indexed citations

Schaer, David, Yanxia Li, Stephen Castaneda, et al.. (2015). Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition. Journal for ImmunoTherapy of Cancer. 3(Suppl 2). P402–P402. 1 indexed citations

Zhang, Yixian, Stephen Castaneda, Melissa Dumble, et al.. (2011). Reduced Expression of the Androgen Receptor by Third Generation of Antisense Shows Antitumor Activity in Models of Prostate Cancer. Molecular Cancer Therapeutics. 10(12). 2309–2319. 41 indexed citations

Sapra, Puja, Yixian Zhang, Stephen Castaneda, et al.. (2009). Abstract C144: A locked nucleic acid antisense oligonucleotode against androgen receptor, down-modulates target mRNA and causes antitumor effects in xenograft models of prostate cancer. Molecular Cancer Therapeutics. 8(12_Supplement). C144–C144. 1 indexed citations

Lee, Francis Y. F., Kelly L. Covello, Stephen Castaneda, et al.. (2008). Synergistic Antitumor Activity of Ixabepilone (BMS-247550) Plus Bevacizumab in Multiple In vivo Tumor Models. Clinical Cancer Research. 14(24). 8123–8131. 37 indexed citations

Luo, Feng, Zheng Yang, Amy Camuso, et al.. (2006). Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure. Clinical Cancer Research. 12(23). 7180–7186. 113 indexed citations

Wild, Robert A., Krista Fager, Christine Flefleh, et al.. (2006). Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels. Molecular Cancer Therapeutics. 5(1). 104–113. 60 indexed citations

Lee, Francis Y., Louis J. Lombardo, Amy Camuso, et al.. (2005). BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo. Cancer Research. 65. 159–159. 38 indexed citations

10.

Luo, Feng, Zheng Yang, Amy Camuso, et al.. (2005). Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. Cancer Chemotherapy and Pharmacology. 56(5). 455–464. 66 indexed citations

11.

Luo, Feng, Zheng Yang, Huijin Dong, et al.. (2005). Prediction of Active Drug Plasma Concentrations Achieved in Cancer Patients by Pharmacodynamic Biomarkers Identified from the Geo Human Colon Carcinoma Xenograft Model. Clinical Cancer Research. 11(15). 5558–5565. 22 indexed citations

12.

Castaneda, Stephen, Ivan Inigo, David Kan, et al.. (2005). Ixabepilone (BMS-247550) plus trastuzumab combination chemotherapy induces synergistic antitumor efficacy in HER2 dependent breast cancers and is accompanied by modulation of molecular response markers. Journal of Clinical Oncology. 23(16_suppl). 561–561. 26 indexed citations

13.

Lee, Francis Y., Louis J. Lombardo, R. M. Borzilleri, et al.. (2004). Pharmacodynamic analysis of target inhibition and tumor endothelial cell death in biopsies obtained from patients treated with the VEGF receptor antagonists SU5416 or SU6668. Cancer Research. 64. 921–921. 3 indexed citations

14.

Wild, Robert A., Stephen Castaneda, Christine Flefleh, et al.. (2004). BMS-354825, a Dual SRC/ABL Kinase Inhibitor, Displays Potent Anti-Tumor Activity in a Model of Intracranial CML Growth.. Blood. 104(11). 1988–1988. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact